Gene expression profiling and prediction of clinical outcome in ovarian cancer

Critical Reviews in Oncology/Hematology

Volumn 72, Issue 2, 2009, Pages 98-109

  Sabatier, Renaud ^a,b   Finetti, Pascal ^a   Cervera, Nathalie ^a   Birnbaum, Daniel ^a   Bertucci, François ^a,b,c  

^a AIX MARSEILLE UNIVERSITY   (France)

^b IPC   (France)

^c AIX MARSEILLE UNIVERSITY   (France)

Author keywords

DNA microarray; Gene expression profiling; Ovarian cancer; Prognosis

Indexed keywords

CISPLATIN; PACLITAXEL; PLATINUM DERIVATIVE; PROTEIN TYROSINE KINASE INHIBITOR; TAXANE DERIVATIVE;

CANCER CHEMOTHERAPY; CANCER RESEARCH; CANCER SURVIVAL; CYTOREDUCTIVE SURGERY; DNA MICROARRAY; DRUG MECHANISM; EPITHELIUM TUMOR; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMAN; LETHALITY; OUTCOMES RESEARCH; OVARY CANCER; PREDICTION; PROGNOSIS; QUANTITATIVE ANALYSIS; REVIEW; SURVIVAL TIME; TREATMENT RESPONSE;

FEMALE; GENE EXPRESSION PROFILING; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OVARIAN NEOPLASMS; PROGNOSIS;

EID: 71749087775     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2009.01.007     Document Type: Review

References (47)

1. Cannistra S.A. Cancer of the ovary. N Engl J Med 351 (2004) 2519-2529
2. Gadducci A., Cosio S., Tana R., and Genazzani A.R. Serum and tissue biomarkers as predictive and prognostic variables in epithelial ovarian cancer. Crit Rev Oncol Hematol 69 (2009) 12-27
3. Bertucci F., Houlgatte R., Nguyen C., Viens P., Jordan B.R., and Birnbaum D. Gene expression profiling of cancer by use of DNA arrays: how far from the clinic?. Lancet Oncol 2 (2001) 674-682
4. Bertucci F., Finetti P., Cervera N., Maraninchi D., Viens P., and Birnbaum D. Gene expression profiling and clinical outcome in breast cancer. Omics 10 (2006) 429-443
5. Ross J.S., Hatzis C., Symmans W.F., Pusztai L., and Hortobagyi G.N. Commercialized multigene predictors of clinical outcome for breast cancer. Oncologist 13 (2008) 477-493
6. Cleator S., Heller W., and Coombes R.C. Triple-negative breast cancer: therapeutic options. Lancet Oncol 8 (2007) 235-244
7. Olivier R.I., van Beurden M., and van' t Veer L.J. The role of gene expression profiling in the clinical management of ovarian cancer. Eur J Cancer 42 (2006) 2930-2938
8. Bristow R.E., Tomacruz R.S., Armstrong D.K., Trimble E.L., and Montz F.J. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 20 (2002) 1248-1259
9. Berchuck A., Iversen E.S., Lancaster J.M., et al. Prediction of optimal versus suboptimal cytoreduction of advanced-stage serous ovarian cancer with the use of microarrays. Am J Obstet Gynecol 190 (2004) 910-925
10. Lancaster J.M., Dressman H.K., Whitaker R.S., et al. Gene expression patterns that characterize advanced stage serous ovarian cancers. J Soc Gynecol Invest 11 (2004) 51-59
11. Spentzos D., Levine D.A., Ramoni M.F., et al. Gene expression signature with independent prognostic significance in epithelial ovarian cancer. J Clin Oncol 22 (2004) 4700-4710
12. Spentzos D., Levine D.A., Kolia S., et al. Unique gene expression profile based on pathologic response in epithelial ovarian cancer. J Clin Oncol 23 (2005) 7911-7918
13. Berchuck A., Iversen E.S., Lancaster J.M., et al. Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers. Clin Cancer Res 11 (2005) 3686-3696
14. Hartmann L.C., Lu K.H., Linette G.P., et al. Gene expression profiles predict early relapse in ovarian cancer after platinum-paclitaxel chemotherapy. Clin Cancer Res 11 (2005) 2149-2155
15. Partheen K., Levan K., Osterberg L., and Horvath G. Expression analysis of stage III serous ovarian adenocarcinoma distinguishes a sub-group of survivors. Eur J Cancer 42 (2006) 2846-2854
16. Bild A.H., Yao G., Chang J.T., et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 439 (2006) 353-357
17. Bonome T., Levine D.A., Shih J., et al. A gene signature predicting for survival in suboptimally debulked patients with ovarian cancer. Cancer Res 68 (2008) 5478-5486
18. Lage H., and Denkert C. Resistance to chemotherapy in ovarian carcinoma. Recent Results Cancer Res 176 (2007) 51-60
19. Cheng T.C., Manorek G., Samimi G., Lin X., Berry C.C., and Howell S.B. Identification of genes whose expression is associated with cisplatin resistance in human ovarian carcinoma cells. Cancer Chemother Pharmacol 58 (2006) 384-395
20. Li J., Wood III W.H., Becker K.G., Weeraratna A.T., and Morin P.J. Gene expression response to cisplatin treatment in drug-sensitive and drug-resistant ovarian cancer cells. Oncogene 26 (2007) 2860-2872
21. Roberts D., Schick J., Conway S., et al. Identification of genes associated with platinum drug sensitivity and resistance in human ovarian cancer cells. Br J Cancer 92 (2005) 1149-1158
22. Whiteside M.A., Chen D.T., Desmond R.A., Abdulkadir S.A., and Johanning G.L. A novel time-course cDNA microarray analysis method identifies genes associated with the development of cisplatin resistance. Oncogene 23 (2004) 744-752
23. Duan Z., Feller A.J., Penson R.T., Chabner B.A., and Seiden M.V. Discovery of differentially expressed genes associated with paclitaxel resistance using cDNA array technology: analysis of interleukin (IL) 6, IL-8 and monocyte chemotactic protein 1 in the paclitaxel-resistant phenotype. Clin Cancer Res 5 (1999) 3445-3453
24. Goto T., Takano M., Sakamoto M., et al. Gene expression profiles with cDNA microarray reveal RhoGDI as a predictive marker for paclitaxel resistance in ovarian cancers. Oncol Rep 15 (2006) 1265-1271
25. Lamendola D.E., Duan Z., Yusuf R.Z., and Seiden M.V. Molecular description of evolving paclitaxel resistance in the SKOV-3 human ovarian carcinoma cell line. Cancer Res 63 (2003) 2200-2205
26. Selvanayagam Z.E., Cheung T.H., Wei N., et al. Prediction of chemotherapeutic response in ovarian cancer with DNA microarray expression profiling. Cancer Genet Cytogenet 154 (2004) 63-66
27. Jazaeri A.A., Awtrey C.S., Chandramouli G.V., et al. Gene expression profiles associated with response to chemotherapy in epithelial ovarian cancers. Clin Cancer Res 11 (2005) 6300-6310
28. Bernardini M., Lee C.H., Beheshti B., et al. High-resolution mapping of genomic imbalance and identification of gene expression profiles associated with differential chemotherapy response in serous epithelial ovarian cancer. Neoplasia 7 (2005) 603-613
29. Krynetski E.Y., Krynetskaia N.F., Bianchi M.E., and Evans W.E. A nuclear protein complex containing high mobility group proteins B1 and B2, heat shock cognate protein 70, ERp60, and glyceraldehyde-3-phosphate dehydrogenase is involved in the cytotoxic response to DNA modified by incorporation of anticancer nucleoside analogues. Cancer Res 63 (2003) 100-106
30. Helleman J., Jansen M.P., Span P.N., et al. Molecular profiling of platinum resistant ovarian cancer. Int J Cancer 118 (2006) 1963-1971
31. Dressman H.K., Berchuck A., Chan G., et al. An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. J Clin Oncol 25 (2007) 517-525
32. Shi L., Reid L.H., Jones W.D., et al. The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements. Nat Biotechnol 24 (2006) 1151-1161
33. Bueno de Mesquita J.M., van Harten W.H., Retel V.P., et al. Use of the 70-gene signature to predict prognosis of patients aged less than 61 years with node-negative breast cancer: a prospective community-based study (RASTER). Lancet Oncol 8 (2007) 1079-1087
34. Hoshida Y., Villanueva A., Kobayashi M., et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med 359 (2008) 1995-2004
35. Hewitt S.M., Lewis F.A., Cao Y., et al. Tissue handling and specimen preparation in surgical pathology: issues concerning the recovery of nucleic acids from formalin-fixed, paraffin-embedded tissue. Arch Pathol Lab Med 132 (2008) 1929-1935
36. Roberts P.C. Gene expression microarray data analysis demystified. Biotechnol Annu Rev 14 (2008) 29-61
37. Quackenbush J. Microarray analysis and tumor classification. N Engl J Med 354 (2006) 2463-2472
38. Brazma A., Hingamp P., Quackenbush J., et al. Minimum information about a microarray experiment (MIAME)-toward standards for microarray data. Nat Genet 29 (2001) 365-371
39. Fan C., Oh D.S., Wessels L., et al. Concordance among gene-expression-based predictors for breast cancer. N Engl J Med 355 (2006) 560-569
40. Ein-Dor L., Kela I., Getz G., Givol D., and Domany E. Outcome signature genes in breast cancer: is there a unique set?. Bioinformatics 21 (2005) 171-178
41. Wirapati P., Sotiriou C., Kunkel S., et al. Meta-analysis of gene-expression profiles in breast cancer: toward a unified understanding of breast cancer sub-typing and prognosis signatures. Breast Cancer Res 10 (2008) R65
42. Cardoso F., Van't Veer L., Rutgers E., Loi S., Mook S., and Piccart-Gebhart M.J. Clinical application of the 70-gene profile: the MINDACT trial. J Clin Oncol 26 (2008) 729-735
43. Sparano J.A., and Paik S. Development of the 21-gene assay and its application in clinical practice and clinical trials. J Clin Oncol 26 (2008) 721-728
44. Bild A.H., Potti A., and Nevins J.R. Linking oncogenic pathways with therapeutic opportunities. Nat Rev Cancer 6 (2006) 735-741
45. Dupuy A., and Simon R.M. Critical review of published microarray studies for cancer outcome and guidelines on statistical analysis and reporting. J Natl Cancer Inst 99 (2007) 147-157
46. McShane L.M., Altman D.G., Sauerbrei W., Taube S.E., Gion M., and Clark G.M. Reporting recommendations for tumor marker prognostic studies. J Clin Oncol 23 (2005) 9067-9072
47. Clayton E.W. Ethical, legal, and social implications of genomic medicine. N Engl J Med 349 (2003) 562-569